Vitality Watch

Dossier rss expert media 03-oct-2026
Content from credentialed experts outside peer review — podcasts, blogs, talks

Myostatin inhibitors and the paradox of larger but weaker muscles

Key claim: Attia argues that myostatin inhibitors (new and old) can preserve or increase lean mass yet paradoxically fail to boost muscle strength.

Abstract

Drugs, new and old, that preserve lean mass, but fail to boost strength The post Myostatin inhibitors and the paradox of larger but weaker muscles appeared first on Peter Attia MD.

Why this matters

Myostatin inhibitors are a recurring longevity-clinic and biohacker interest because ‘more lean mass’ sounds like a direct answer to sarcopenia. Attia’s framing surfaces a divergence the trend tends to obscure: cross-trial, the drugs do enlarge muscle but fail to reliably increase strength — the outcome that actually tracks healthspan. The gap between the marketed proxy (mass) and the functional endpoint (strength) is the story.

Source

Link

Briefing card

Myostatin inhibitors and the paradox of larger but weaker muscles
Stage: expert media · rss · 03-oct-2026

If you are tracking myostatin-pathway drugs as a sarcopenia play, note that trials to date have shown muscle growth without reliable strength gains.

Attia argues that myostatin inhibitors (new and old) can preserve or increase lean mass yet paradoxically fail to boost muscle strength.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: url:https://peterattiamd.com/myostatin-inhibitors-and-larger-but-weaker-muscles/

build build 880 · 2bcef25 · 2026-11-18